Progress towards the prevention and treatment of norovirus infections

Future Microbiology

Volumn 8, Issue 11, 2013, Pages 1475-1487

  Arias, Armando ^a   Emmott, Edward ^a   Vashist, Surender ^a   Goodfellow, Ian ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

antiviral; calicivirus; gastroenteritis; host factors; norovirus; vaccine; viral polymerase; virus like particles; VLP

Indexed keywords

2' ARAURIDINE; 2' METHYLCYTIDINE; 2' METHYLCYTIDINE DERIVATIVE; 3' DEOXYURIDINE; ALDEHYDE; ANTIVIRUS AGENT; BLOOD GROUP ANTIGEN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CITRIC ACID; FAVIPIRAVIR; FE 15; FUCOSE; HEPARIN; HIPPURISTANOL; INTERFERON; MYCOPHENOLIC ACID; NF 023; NOROVIRUS VACCINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE INHIBITOR; ROTAVIRUS VACCINE; SMALL INTERFERING RNA; STYRYLCHROMONE; SURAMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE; WP 1130;

ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CALICIVIRUS; CELL CULTURE; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; EPIDEMIC; FOOD CONTAMINATION; FOOD POISONING; FOOD SAFETY; HAND WASHING; HUMAN; HYGIENE; IC 50; INFECTION CONTROL; INFECTION PREVENTION; LIFE CYCLE; NONHUMAN; NOROVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; RNA SYNTHESIS; TARGET CELL; VIRAL GASTROENTERITIS; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS GENOME; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS TRANSMISSION; WASTE MANAGEMENT;

ANIMALS; ANTIVIRAL AGENTS; CALICIVIRIDAE INFECTIONS; HUMANS; INFECTION CONTROL; NOROVIRUS;

EID: 84888212208     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.109     Document Type: Review

References (83)

1. Lopman B, Gastañaduy P, Park G.W., Hall AJ, Parashar UD, Vinjé J. Environmental transmission of norovirus gastroenteritis. Curr. Opin. Virol. 2(1), 96-102 (2012).
2. Batz MB, Hoffmann S, Morris JG Jr. Ranking the disease burden of 14 pathogens in food sources in the United States using attribution data from outbreak investigations and expert elicitation. J. Food Prot. 75, 1278-1291 (2012).
3. Payne DC, Vinjé J, Szilagyi PG et al. Norovirus and medically attended gastroenteritis in US children. N. Engl. J. Med. 368(12), 1121-1130 (2013).
4. Bok K, Green KY Norovirus gastroenteritis in immunocompromised patients. N. Engl. J. Med. 367(22), 2126-2132 (2012).
5. Duizer E, Schwab KJ, Neill F.H., Atmar RL, Koopmans MP, Estes MK Laboratory efforts to cultivate noroviruses. J. Gen. Virol. 85(Pt 1), 79-87 (2004). (Pubitemid 38128872)
6. Chang KO, Sosnovtsev SV, Belliot G, King A.D., Green KY Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line. Virology 353(2), 463-473 (2006). (Pubitemid 44419417)
7. Karst SM, Wobus CE, Lay M, Davidson J., Virgin HW STAT1-dependent innate immunity to a Norwalk-like virus. Science 299(5612), 1575-1578 (2003). (Pubitemid 36297707)
8. Vashist S, Bailey D, Putics A., Goodfellow I. Model systems for the study of human norovirus biology. Future Virol. 4(4), 353-367 (2009).
9. Donaldson EF, Lindesmith LC, Lobue A.D., Baric RS Viral shape-shifting: norovirus evasion of the human immune system. Nat. Rev. Microbiol. 8(3), 231-241 (2010).
10. Kendall M, Mody R, Mahon B., Doyle M, Herman K, Tauxe R. Emergence of salsa and guacamole as frequent vehicles of foodborne disease outbreaks in the United States, 1973-2008. Foodborne Pathog. Dis. 10(4), 316-322 (2013).
11. Wang J, Deng Z. Detection and forecasting of oyster norovirus outbreaks: recent advances and future perspectives. Mar. Environ. Res. 80, 62-69 (2012).
12. Richards GP. Critical review of norovirus surrogates in food safety research: rationale for considering volunteer studies. Food Environ. Virol. 4(1), 6-13 (2012).
13. Park GW, Barclay L, Macinga D., Charbonneau D, Pettigrew CA, Vinjé J. Comparative efficacy of seven hand sanitizers against murine norovirus, feline calicivirus, and GII.4 norovirus. J. Food Protect. 73(12), 2232-2238 (2010).
14. Edmonds SL, McCormack RR, Zhou S.S., Macinga DR, Fricker CM Hand hygiene regimens for the reduction of risk in food service environments. J. Food Protect. 75(7), 1303-1309 (2012).
15. Bentley K, Dove BK, Parks S.R., Walker JT, Bennett AM Hydrogen peroxide vapour decontamination of surfaces artificially contaminated with norovirus surrogate feline calicivirus. J. Hosp. Infect. 80 (2), 116-121 (2012).
16. Greig JD, Lee MB A review of nosocomial norovirus outbreaks: infection control interventions found effective. Epidemiol. Infect. 140(7), 1151-1160 (2012).
17. Rao S, Scattolini de Gier N, Caram LB, Frederick J, Moorefield M, Woods CW. Adherence to self-quarantine recommendations during an outbreak of norovirus infection. Infect. Control Hosp. Epidemiol. 30(9), 896-899 (2009).
18. Zhang Y, Yao Q, Xia C., Jiang X, Wang PG Trapping norovirus by glycosylated hydrogels: a potential oral antiviral drug. Chem. Med. Chem. 1(12), 1361-1366 (2006).
19. Tan M, Jiang X. Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends Microbiol. 19(8), 382-388 (2011).
20. Dai YC, Wang YY, Zhang XF et al. Evaluation of anti-norovirus IgY from egg yolk of chickens immunized with norovirus P particles. J. Virol. Methods 186(1-2), 126-131 (2012).
21. Richardson C, Bargatze RF, Goodwin R, Mendelman PM Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Expert Rev. Vaccines 12(2), 155-167 (2013).
22. Harrington PR, Lindesmith L, Yount B., Moe CL, Baric RS Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J. Virol. 76(23), 12335-12343 (2002). (Pubitemid 35304332)
23. Estes MK, Ball JM, Guerrero RA et al. Norwalk virus vaccines: challenges and progress. J. Infect. Dis. 181(Suppl. 2), S367-S373 (2000). (Pubitemid 30395092)
24. Bartsch SM, Lopman BA, Hall A.J., Parashar UD, Lee BY The potential economic value of a human norovirus vaccine for the United States. Vaccine 30(49), 7097-7104 (2012).
25. Herbst-Kralovetz M., Mason HS, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev. Vaccines 9(3), 299-307 (2010).
26. Atmar RL, Bernstein DI, Harro CD et al. Norovirus vaccine against experimental human Norwalk virus illness. N. Engl. J. Med. 365(23), 2178-2187 (2011).
27. Guerrero RA, Ball JM, Krater S.S., Pacheco SE, Clements JD, Estes MK Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75(20), 9713-9722 (2001). (Pubitemid 32900106)
28. Velasquez LS, Hjelm BE, Arntzen C.J., Herbst-Kralovetz MM.An intranasally delivered Tolllike receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin. Vaccine Immunol. 17(12), 1850-1858 (2010).
29. Bok K, Parra GI, Mitra T et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc. Natl Acad. Sci. USA 108(1), 325-330 (2011).
30. Guix S, Asanaka M, Katayama K et al. Norwalk virus RNA is infectious in mammalian cells. J. Virol. 81(22), 12238-12248 (2007). (Pubitemid 350085839)
31. Murakami K, Kurihara C, Oka T et al. Norovirus binding to intestinal epithelial cells is independent of histo-blood group antigens. PLoS ONE 8(6), e66534 (2013).
32. Tamura M, Natori K, Kobayashi M., Miyamura T, Takeda N. Genogroup II noroviruses efficiently bind to heparan sulfate proteoglycan associated with the cellular membrane. J. Virol. 78(8), 3817-3826 (2004). (Pubitemid 38437187)
33. Taube S, Perry J W, Yetming K et al. Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses. J. Virol. 83(9), 4092-4101 (2009).
34. Gerondopoulos A, Jackson T, Monaghan P., Doyle N, Roberts LO Murine norovirus-1 cell entry is mediated through a non-clathrin-, non-caveolae-, dynamin- and cholesterol-dependent pathway. J. Gen. Virol. 91(Pt 6), 1428-1438 (2010).
35. Perry JW, Wobus CE Endocytosis of murine norovirus 1 into murine macrophages is dependent on dynamin II and cholesterol. J. Virol. 84(12), 6163-6176 (2010).
36. Daughenbaugh KF, Fraser CS, Hershey J W, Hardy ME The genome-linked protein VPg of the Norwalk virus binds eIF3, suggesting its role in translation initiation complex recruitment. Eur. Mol. Biol. Org. J. 22(11), 2852-2859 (2003). (Pubitemid 36712380)
37. Goodfellow I, Chaudhry Y, Gioldasi I et al. Calicivirus translation initiation requires an interaction between VPg and eIF4E. EMBO Rep. 6(10), 968-972 (2005). (Pubitemid 41521953)
38. Ettayebi K, Hardy ME Norwalk virus nonstructural protein p48 forms a complex with the SNARE regulator VAP-A and prevents cell surface expression of vesicular stomatitis virus G protein. J. Virol. 77(21), 11790-11797 (2003). (Pubitemid 37271676)
39. Hyde JL, Sosnovtsev SV, Green K.Y., Wobus C., Virgin H W, Mackenzie JM Mouse norovirus replication is associated with virus-induced vesicle clusters originating from membranes derived from the secretory pathway. J. Virol. 83(19), 9709-9719 (2009).
40. Hyde JL, Gillespie LK, Mackenzie JM Mouse norovirus 1 utilizes the cytoskeleton network to establish localization of the replication complex proximal to the microtubule. J. Virol. 86(8), 4110-4122 (2012).
41. Hansman GS, Shahzad-Ul-Hussan S, McLellan JS et al. Structural basis for norovirus inhibition and fucose mimicry by citrate. J. Virol. 86(1), 284-292 (2012).
42. Rademacher C, Guiard J, Kitov PI et al. Targeting norovirus infection-multivalent entry inhibitor design based on NMR experiments. Chemistry 17(27), 7442-7453 (2011).
43. Feng X, Jiang X. Library screen for inhibitors targeting norovirus binding to histo-blood group antigen receptors. Antimicrob. Agents Chemother. 51(1), 324-331 (2007). (Pubitemid 46047722)
44. Chaudhry Y, Nayak A, Bordeleau ME et al. Caliciviruses differ in their functional requirements for eIF4F components. J. Biol. Chem. 281(35), 25315-25325 (2006). (Pubitemid 44401919)
45. Tsumuraya T, Ishikawa C, Machijima Y et al. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem. Pharmacol. 81(6), 713-722 (2011).
46. Leen EN, Kwok KY, Birtley JR et al. Structures of the compact helical core domains of feline calicivirus and murine norovirus VPg proteins. J. Virol. 87(10), 5318-5330 (2013).
47. Mandadapu SR, Gunnam MR, Tiew KC et al. Inhibition of norovirus 3CL protease by bisulfite adducts of transition state inhibitors. Bioorg. Med. Chem. Lett. 23(1), 62-65 (2013).
48. Kim Y, Lovell S, Tiew KC et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. 86 (21), 11754-11762 (2012).
49. Bok K, Cavanaugh VJ, Matson DO et al. Inhibition of norovirus replication by morpholino oligomers targeting the 5'-end of the genome. Virology 380(2), 328-337 (2008).
50. Rohayem J, Bergmann M, Gebhardt J et al. Antiviral strategies to control calicivirus infections. Antiviral Res. 87(2), 162-178 (2010).
51. de Fougerolles A., Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6(6), 443-453 (2007). (Pubitemid 47064567)
52. Chang KO, George DW Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells. J. Virol. 81(22), 12111-12118 (2007). (Pubitemid 350085826)
53. Changotra H, Jia Y, Moore TN et al. Type I and type II interferons inhibit the translation of murine norovirus proteins. J. Virol. 83 (11), 5683-5692 (2009).
54. Rohayem J, Robel I, Jäger K, Scheffler U., Rudolph W. Protein-primed and de novo initiation of RNA synthesis by norovirus 3Dpol. J. Virol. 80(14), 7060-7069 (2006). (Pubitemid 44025203)
55. Belliot G, Sosnovtsev S V, Chang KO, McPhie P, Green KY Nucleotidylylation of the VPg protein of a human norovirus by its proteinase-polymerase precursor protein. Virology 374(1), 33-49 (2008).
56. Agudo R, Arias A, Domingo E. 5-fluorouracil in lethal mutagenesis of foot-and-mouth disease virus. Future Med. Chem. 1(3), 529-539 (2009).
57. Graci JD, Cameron CE Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16(1), 37-48 (2006). (Pubitemid 43133592)
58. Rocha-Pereira J., Jochmans D, Dallmeier K et al. Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine. Biochem. Biophys. Res. Comm. 427(4), 796-800 (2012).
59. Costantini V.P., Whitaker T, Barclay L et al. Antiviral activity of nucleoside analogs against norovirus. Antiviral Ther. 17(6), 981-991 (2012).
60. Afdhal N, O'Brien C, Godofsky E et al. Valopicitabine (NM 283), alone or with peg-interferon, compared with peg-interferon/ribavirin (PEGIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to PEGIFN/RBV: one year results. J. Hepatol. 46, S5 (2007).
61. Carroll SS, Koeplinger K, Vavrek M et al. Antiviral efficacy upon administration of a HepDirect prodrug of 2'-C-methylcytidine to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother. 55(8), 3854-3860 (2011).
62. Rocha-Pereira J., Jochmans D, Dallmeier K., Leyssen P, Nascimento MS, Neyts J. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem. Biophys. Res. Comm. 424(4), 777-780 (2012).
63. Baranovich T, Wong SS, Armstrong J et al. T-705 (Favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J. Virol. 87(7), 3741-3751 (2013).
64. Mastrangelo E, Pezzullo M, Tarantino D et al. Structure-based inhibition of norovirus RNA-dependent RNA-polymerases. J. Mol. Biol. 419(3-4), 198-210 (2012).
65. McGeary RP, Bennett AJ, Tran Q.B., Cosgrove KL, Ross BP Suramin: clinical uses and structure-activity relationships. Mini Rev. Med. Chem. 8(13), 1384-1394 (2008).
66. Rocha-Pereira J., Cunha R, Pinto D.C., Silva AM, Nascimento MS (E)-2-styrylchromones as potential anti-norovirus agents. Bioorg. Med. Chem. 18(12), 4195-4201 (2010).
67. Kwong AD, Rao BG, Jeang KT Viral and cellular RNA helicases as antiviral targets. Nat. Rev. Drug Discov. 4(10), 845-853 (2005). (Pubitemid 41553965)
68. Pfister T, Wimmer E. Polypeptide p41 of a Norwalk-like virus is a nucleic acid-independent nucleoside triphosphatase. J. Virol. 75(4), 1611-1619 (2001). (Pubitemid 32110150)
69. Norder H, De Palma AM, Selisko B et al. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res. 89(3), 204-218 (2011).
70. Gutiérrez-Escolano A.L., Vázquez-Ochoa M, Escobar-Herrera J, Hernández-Acosta J. La, PTB, and PAB proteins bind to the 3(') untranslated region of Norwalk virus genomic RNA. Biochem. Biophys. Res. Comm. 311(3), 759-766 (2003). (Pubitemid 37377722)
71. Vashist S, Urena L, Chaudhry Y., Goodfellow I. Identification of RNA-protein interaction networks involved in the norovirus life cycle. J. Virol. 82(22), 4449-4460 (2012).
72. Reineke LC, Lloyd RE Animal virus schemes for translation dominance. Curr. Opin. Virol. 1(5), 363-372 (2011).
73. Maga G, Falchi F, Radi M et al. Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation. Chem. Med. Chem. 6(8), 1371-1389 (2011).
74. Schröder M. Viruses and the human DEAD-box helicase DDX3: inhibition or exploitation? Biochem. Soc. Trans. 39(2), 679-683 (2011).
75. Soto-Rifo R., Ohlmann T. The role of the DEAD-box RNA helicase DDX3 in mRNA metabolism. Wiley Interdiscip. Rev. RNA 4(4), 369-385 (2013).
76. Tang J, Huang ZM, Chen Y.Y., Zhang ZH, Liu GL, Zhang J. A novel inhibitor of human La protein with anti-HBV activity discovered by structure-based virtual screening and in vitro evaluation. PLoS ONE 7(4), e36363 (2012).
77. Maraia RJ, Bayfield MA The La protein-RNA complex surfaces. Mol. Cell 21(2), 149-152 (2006). (Pubitemid 43099931)
78. Bailey D, Karakasiliotis I, Vashist S et al. Functional analysis of RNA structures present at the 3' extremity of the murine norovirus genome: the variable polypyrimidine tract plays a role in viral virulence. J. Virol. 84(6), 2859-2870 (2010).
79. Karakasiliotis I, Vashist S, Bailey D et al. Polypyrimidine tract binding protein functions as a negative regulator of feline calicivirus translation. PLoS ONE 5(3), 17 (2010).
80. Chen M, Zhang J, Manley JL Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res. 70(22), 8977-8980 (2010).
81. Manita D, Toba Y, Takakusagi Y et al. Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction. Bioorg. Med. Chem. 19(24), 7690-7697 (2011).
82. Perry JW, Ahmed M, Chang K.O., Donato NJ, Showalter HD, Wobus CE Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response. PLoS Pathog. 8(7), e1002783 (2012).
83. Jabbari B. Botulinum neurotoxins in the treatment of refractory pain. Nat. Clin. Prac. Neurol. 4(12), 676-685 (2008).